Anthropic Acquires Coefficient Bio for $400 Million, Deepening Its Push Into AI‑Driven Drug Discovery
Anthropic, the San Francisco‑based AI safety and research company behind Claude, has acquired Coefficient Bio, a New York‑based stealth biotech AI startup, in an all‑stock deal valued at just over $400 million, according to reporting by The Information and Eric Newcomer confirmed through TechCrunch. The acquired team will join Anthropic's Healthcare and Life Sciences group, led by Eric Kauderer‑Abrams, who was brought in during mid‑2025 with an explicit mandate to build Anthropic's presence in scientific and medical AI workflows.
The deal is striking for several reasons, not least of which is the age of the company being acquired. Coefficient Bio was formally founded approximately eight months before the acquisition, around August 2025, and had fewer than ten employees at the time the deal closed. It had no publicly disclosed product, no disclosed revenue, and no conventional commercial traction metrics by which most acquisitions are measured. What it did have was a founding team with credentials that very few early‑stage AI biotech companies can match.
Samuel Stanton and Nathan C. Frey, Coefficient Bio's co‑founders, both came from Prescient Design, Genentech's computational drug discovery unit, which has become one of the most consequential talent nurseries for AI‑native biotech companies. Frey served as Group Leader and Principal Machine Learning Scientist at Prescient Design, where he led biological foundation models, autonomous antibody design, and established Genentech's collaboration with Nvidia. He holds PhD‑level affiliations with MIT, Penn, and Berkeley Lab, won an ICLR Outstanding Paper Award in 2024 for novel generative modeling applied to drug candidate discovery, and was recently named a 2026 Termeer Fellow, a selective biotech leadership program. Stanton was also an ML scientist at Prescient Design before co‑founding Coefficient Bio.
The startup was backed by Dimension, a New York‑based venture firm focused on the intersection of technology and life sciences, which held roughly half the company. Dimension was founded in 2023 by former Lux Capital and Obvious Ventures partners and is reportedly raising a third fund of approximately $700 million to double down on the same AI‑biology thesis. The firm's internal rate of return on the Coefficient Bio investment, given the timeline and exit price, reflects the extraordinary speed at which AI valuations are repricing early‑stage science bets.
Against Anthropic's $380 billion post‑money valuation from its February 2026 Series G, the $400 million acquisition represents roughly 0.1 percent dilution. It is, as observers have noted, less a bet on what Coefficient Bio had built and more a statement about what Anthropic believes it can build with those specific researchers on the team. Drug development is not the kind of market where you hire in volume. It is the kind of market where the right ten people, given the right resources and platform, can produce outcomes that matter.
Anthropic's life sciences strategy leading into this acquisition had centered on adapting Claude's general‑purpose capabilities for scientific workflows through integrations. The company's Claude for Life Sciences offering, announced in October 2025, positioned Claude as a research partner embedded in scientific environments with connectors into PubMed, Benchling, ClinicalTrials.gov, and regulatory drafting workflows. Coefficient Bio's team, with deep expertise in autonomous scientific agents, probabilistic modeling, and molecular decision‑making, represents a more aggressive vertical move: Anthropic is no longer merely adapting its general model for science. It is acquiring researchers who have built systems designed specifically to function in biopharma's most complex and consequential decision environments.
The broader context for this deal is a pharmaceutical industry undergoing a genuine structural transformation around AI. Google DeepMind spun off Isomorphic Labs to pursue AI‑designed drug candidates now entering clinical trials. Nvidia announced a five‑year partnership with Eli Lilly to build an AI co‑innovation lab for accelerated drug discovery. OpenAI has been working with Moderna to speed the development of personalized cancer vaccines. For whichever frontier AI model becomes embedded in biopharma R&D workflows, the revenue opportunity is enormous and recurring. A single approved drug can generate billions. The AI platform that reliably accelerates discovery timelines captures a meaningful share of that value through long‑term enterprise contracts.
Coefficient Bio's stated ambition, as articulated by Stanton in a January 2026 recruiting post, was to usher biopharma into the Intelligence Age, fundamentally changing how the industry learns and makes decisions. That is a much larger and more defensible market than the headline of "AI discovers drugs" implies. What Coefficient's team was building was not a molecule generator. It was a platform for compressing the decision loops that govern every phase of drug development, from target identification and compound screening through clinical trial planning and regulatory strategy to organizational knowledge management. Anthropic is buying the team to own that decision layer.
For the AI and biotech investment ecosystem, this acquisition sends several signals. First, that the talent premium for frontier computational biology researchers is now priced in hundreds of millions of dollars for teams of fewer than ten people. Second, that frontier AI labs are willing to make vertical bets before commercial proof exists, and are counting on the depth of the team to generate that proof. Third, that the convergence of AI and life sciences is no longer a research hypothesis but a capital allocation strategy at the highest levels of the industry.